Zacks Investment Research
17 Jul 2026, 19:32 UTC · 13w ago
Verdict
Headline takes no side. We score QURE +0.20 across four claims — slightly bullish.
+0.20slightly bullish
More positive than 57% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
uniQure's lead gene therapy candidate for Huntington's disease, AMT-130, has driven a 124.4% stock price increase over the last 12 weeks.
More positive than 94% of claims this week
uniQure's price-to-book value of 16.48X is significantly higher than both its industry average (2.59X) and the S&P 500 (3.69X).
So whatExtreme valuation premiums increase the risk of a price correction if clinical or regulatory milestones are delayed.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 84% of claims this week
uniQure's first-quarter 2026 revenue of $3.6 million missed the Zacks Consensus Estimate of $7 million.
More negative than 76% of claims this week
Selling, general and administrative expenses rose 84% to $20.1 million due to commercial hiring and AMT-130 launch preparations.
So whatIncreased operational spending reinforces a near-term loss profile and elevates the cash burn rate.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The stock has surged on positive reassessment of its lead candidate, although the analyst warns of a high valuation and mixed quarterly results.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as another stock to monitor in the Huntington's disease space without specific news.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as another stock to monitor in the Huntington's disease space without specific news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
More positive than 14% of relationship scores this week
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
More positive than 14% of relationship scores this week
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
More positive than 14% of relationship scores this week
[mutual] Both companies are identified as Huntington's disease-related stocks for investors to monitor.
−42.4%
Price is moving against the score
$22.69 vs $39.36 close before publication (Jul 16) · not market-adjusted
QURE chart →
